Anticancer properties of 5Z-(4-fluorobenzylidene)-2-(4-hydroxyphenylamino)-thiazol-4-one

Konrad A. Szychowski1,2, Danylo V. Kaminskyy3, Marcin L. Leja3, Anna P. Kryshchyshyn3, Roman B. Lesyk2,1, Jakub Tobiasz2, Maciej Wnuk4, Tadeusz Pomianek5 & Jan Gmiński2

4-thiazolidinones, which are privileged structures in medicinal chemistry, comprise the well-known class of heterocycles and are a source of new drug-like compounds. Undoubtedly, the 5-bulky-substituted-2,4-thiazolidinediones - a class of antihyperglycemic glitazones, which are peroxisome proliferator-activated receptor gamma (PPARγ) agonists, are the most described group among them. As there are various chemically distinct 4-thiazolidinones, different subtypes have been selected for studies; however, their main pharmacological profiles are similar. The aim of this study was to evaluate the anticancer activity of 5Z-(4-fluorobenzylidene)-2-(4-hydroxyphenylamino)-thiazol-4-one (Les-236) in four human cancer cell lines, A549, SCC-15, SH-SY5Y, and CACO-2, and investigate its impact on the production of reactive oxygen species (ROS) and the apoptotic process as well as cytotoxicity and metabolism in these cell lines. The cell lines were exposed to increasing concentrations (1 nM to 100 µM) of the studied compound for 6, 24, and 48 h, and later, ROS production, cell viability, caspase-3 activity, and cell metabolism were examined. The obtained results showed that the studied compound decreased the production of ROS, increased the release of lactate dehydrogenase, and decreased cell metabolism/proliferation in all the five cell lines at micromolar concentrations. Interestingly, over a wide range of concentrations (from 1 nM to 100 µM), Les-236 was able to increase the activity of caspase-3 in BJ (after 6 h of exposure), A549, CACO-2, and SCC-15 (after 48 h of exposure) cell lines which could be an effect of the activation of PPARγ-dependent pathways.

4-thiazolidinones are a widely studied class of heterocycles, which are considered as privileged structures in medicinal chemistry, and a source of new drug-like compounds1,2. Undoubtedly, the 5-bulky-substituted-2,4-thiazolidinediones, a class of antihyperglycemic glitazones, which are peroxisome proliferator-activated receptor gamma (PPARγ) agonists, are the most described group among them. As there are various chemically distinct 4-thiazolidinones, different subtypes have been selected for investigations; however, their main pharmacological profiles are similar and they are known to exhibit anticancer, anti-inflammatory, antiviral, and antimicrobial activity. Moreover, different 4-thiazolidinones (2,4-thiazolidinone, rhodanine, 2-amino(imino)-4-thiazolidinone, etc.), and their related (hydantoin) cores are considered as bioisosteres. 5-ene-2-amino(imino)-4-thiazolidinones represent one of the most studied subtypes of 4-thiazolidinones. The importance of C5-ene fragment had been proved in many studies4-6. Moreover, conjugation of the C5 exocyclic double bond to the C4 carbonyl group makes these compounds electrophilic and potentially reactive in Michael addition. This is one of the reasons why 5-ene-4-thiazolidinones, especially rhodanes, are called as pan-assay interference compounds7-9. This concept is still under debate; however, many useful properties of Michael acceptors have been proposed7,9,10: Michael acceptors, among the most effective activators of Nrf2, open new perspectives in the treatment of inflammation and cancer11. They act as inducers of phase 2 enzymes and a group of inducible proteins12 and covalent inhibitors13. Moreover, Michael acceptors function as reactive electrophilic species, one of the key signaling species14.

1Department of Pharmaceutical, Organic and Bioorganic Chemistry, Danylo Halytsky Lviv National Medical University, Pekarska 69, Lviv, 79010, Ukraine. 2Department of Public Health, Dietetics and Lifestyle Disorders, Faculty of Medicine, University of Information Technology and Management in Rzeszow, Sucharskiego 2, 35–225, Rzeszow, Poland. 3Postgraduate School of Molecular Medicine, Medical University of Warsaw, Zwirki i Wigury 61, 02–091, Warsaw, Poland. 4Department of Genetics, Faculty of Biotechnology, University of Rzeszow, Pigania 1, 35–310, Rzeszow, Poland. 5Department of Management, Faculty of Administration and Social Sciences, University of Information Technology and Management, Sucharskiego 2, 35–225, Rzeszow, Poland. Correspondence and requests for materials should be addressed to K.A.S. (email: konrad.szychowski@gmail.com)
Among the 5-ene-2-aminoo(imino)-4-thiazolidinones, active anticancer agents which are capable of inhibiting the growth of cancer cells were identified both in screening campaigns and small-scale studies. Many ligands exhibiting high affinity to the known anticancer targets were also described, including integrin αV33 antagonists, inhibitors of CDK1/cyclin B3,34, PPAR antagonists, estrogen-related receptor-α modulators, SHP-2 inhibitors, PTP1B inhibitors, DNA-binding agents (which bind with the DNA minor grove involving van der Waals, H-bonding, and hydrophobic interactions), and so on. Very few attempts have been made to outline the main molecular modes of action of 5-ene-2-aminoo(imino)-4-thiazolidinones1,30. Analyses of the molecular mechanisms of their action revealed their role in the following processes: induction of apoptosis, cell cycle arrest31–33, PPAR-related pathways20,25, inhibition of necroptosis34,35, and modulation of Red/Ox signaling and production of reactive oxygen species (ROS). Sometimes contrasting results are presented for such compounds; for example, one study reported that these compounds decrease the level of ROS36, whereas some other studies reported that the action of these compounds is associated with increase in the production of ROS32,37. The PPAR-related mechanism behind the anticancer effect was actively discussed following the identification of the role of ligand-activated transcription factor. PPARγ regulates diverse functions, such as the development of fat cells and their capacity to store lipids, expression of genes related to metabolic processes, inflammation, cell migration, apoptosis, and cell sensitivity to insulin. Moreover, in 1997, the first reports published highlighted PPARγ as a novel cancer therapeutic target regulating the differentiation of cancer cells38,39. Glitazones induce a variety of favorable changes in several malignancies, including liposarcoma and cancers of various organs such as breast, colon, pancreas, and prostate. In vitro exposure of tumor cells to high doses of troglitazone and ciglitazone was found to lead to cell cycle arrest, apoptosis, and redifferentiation42–44, suggesting the involvement of PPARγ signaling pathways. Furthermore, the in vivo anticancer efficacy of troglitazone was demonstrated in a few clinical studies that involved patients with liposarcomas or prostate cancer45. The precise mechanism of anti-proliferative activities of PPARγ agonists remains unclear46; increasing evidence indicates that 4-thiazolidinones mediate PPARγ-independent antitumor effects by targeting a wide range of signaling pathways controlling the proliferation and survival of cancer cells. Analyses of the effects of 5-ene-2-aminoo(imino)-4-thiazolidinones also revealed the importance of these metabolic pathways in anticancer activity1,2. Additionally, it should be highlighted that anticancer agents such as 5-[(4-methylphenyl)methylene]-2-(phenylamino)-4(5 H)-thiazolone (MMPT) and 5-2,4-dihydroxybenzylidene)-2-(phenylimino)-1,3-thiazolidine are also effective in the treatment of multidrug-resistant cancer18,31,47. The structure of MMPT has been considered as a “pharmacophore model” for further optimization41, and a set of structural requirements were proposed: an unsubstituted N3 atom in the main core, a C5 p-substituted-arylidene moiety, and a C2-arylamino fragment which can be substituted in different positions46. Moreover, MMPT analogs were found to exert anti-inflammatory activity through COX/LOX inhibition46. Other different activities of the related compounds are also being studied. The pharmacological profiles of compounds with anticancer effect and compounds exerting a combination of anticancer, antioxidation, anti-inflammatory,49, and antiprototozoal50 effects are gaining interest. The present work is an extension of our ongoing efforts in the search for new 4-thiazolidinone-based anticancer agents18,31,47. Therefore, the aim of this study was to evaluate the anticancer activity of 5Z-(4-fluorobenzylidene)-2-(4-hydroxyphenylamino)-thiazol-4-one (Les-236) in four human cancer cell lines A549, SCC-15, SH-SYSY, and CACO-2, and investigate its impact on ROS production and the apoptotic process as well as cytotoxicity and metabolism in these cell lines (Fig. 1).

Results
Les-236 decreases ROS production in cancerous cell lines. After 3 h of exposure, only 10, 50, and 100 µM concentrations of Les-236 were found to decrease ROS production in the BJ, A549, and SH-SYSY cell lines by 14.37–39.37% compared to control. In CACO-2 and SCC-15 cell lines, Les-236 decreased ROS production at the studied concentrations (1 nM to 100 µM) by 17.10–42.83% compared to control (Fig. 2A). Similarly, in the SH-SYSY cell line, after 6 h of exposure only 10, 50, and 100 µM concentrations of Les-236 decreased ROS production by 16.05–33.29% compared to control. In BJ and A549 cells, Les-236 decreased ROS production at all micromolar concentrations tested (1, 10, 50, and 100 µM) by 18.33–29.13% compared to control. In CACO-2 and

Figure 1. Structure of the studied compound Les-236.
SCC-15 cell lines, the effect of Les-236 was more pronounced and a decrease in ROS production by 21.12–46.95% was observed compared to control (Fig. 2B). After 24 h incubation with BJ, A549, and SH-SY5Y cell lines, Les-236 decreased ROS production by 18.93–35.29% at all micromolar concentrations tested (1, 10, 50, and 100 µM) compared to control. Similarly, Les-236 decreased ROS production at all the studied concentrations in CACO-2 and SCC-15 cell lines (by 16.82–53.35%, compared to control) (Fig. 2C).

The conducted experiments showed that after 6 h of cell co-treatment with Les-236 and hydrogen peroxide (H₂O₂), ROS production stimulated by H₂O₂ was significantly decreased by Les-236. The strongest effect of Les-236 was observed in BJ cells and the weakest in A549 cells (Fig. 3).

**Les-236 increases lactate dehydrogenase (LDH) release from cancerous cell lines.** After 6 h of exposure to Les-236, LDH release was not observed in any of the studied cell lines (Fig. 4A). However, after 24 h of exposure, we observed an increase in LDH release at 10, 50, and 100 µM concentrations of Les-36 in SCC-15, BJ, and SH-SY5Y cell lines. In the SCC-15 cell line, LDH release was increased by 29.85%, 82.28%, and 90.92%, respectively, compared to control. In the BJ cell line, LDH release was increased by 34.28%, 55.10%, and 40.0%, respectively, compared to control. In the SH-SY5Y cell line, LDH release was increased by 20.81%, 20.81%, and 22.54%, respectively, compared to control (Fig. 4B). After 48 h of exposure to Les-236, we observed an increase in LDH release at concentrations of 1, 10, 50, and 100 µM in SCC-15 and SH-SY5Y cell lines. In the SCC-15 cell line, LDH release was increased by 39.93%, 30.82%, 93.90%, and 123.40%, respectively, compared to control. In the SH-SY5Y cell line, LDH release was increased by 50.0%, 59.70%, 48.51%, and 56.72%, respectively, compared to control. In the BJ and CACO-2 cell lines, Les-236 stimulated LDH release occurred only at the highest concentrations tested.
micromolar concentrations (10, 50, and 100 µM). In the BJ cell line, LDH release was increased by 116.10%, 239.51%, and 177.32%, respectively, compared to control. In the CACO-2 cell line, LDH release was increased by 12.16%, 13.85%, and 21.96%, respectively, compared to control. In the A549 cell line, only at 50 and 100 µM concentration of Les-36, an increase (Fig. 4C) in LDH release was observed (23.67% and 14.89%, respectively, compared to control). The half maximal effective concentrations (EC50) were calculated for LDH release to determine the dose-dependent effect on cell lethality (Table 1).

Les-236 decreases resazurin reduction in cancerous cell lines. After 6 h of exposure to Les-236, we observed a decrease in resazurin reduction by 18.25–19.08% in BJ and CACO-2 cell lines compared to control at concentrations of 10, 50, and 100 µM. In SH-SY5Y, A549, and SCC-15 cell lines, we did not observe any change in resazurin reduction (Fig. 5A). After 24 h of exposure to Les-236, we observed a decrease in resazurin reduction in A549 and BJ cell lines at 10, 50, and 100 µM (by 19.59%, 20.24%, and 19.23%, respectively, for A549 and by

Figure 3. Effect of Les-236 and H₂O₂ on ROS production in cultured human cell lines after 6 h of exposure. The data are presented as means ± SD of three independent experiments. Each treatment was repeated six times (n = 6), and the values were measured in triplicate. *p < 0.05, **p < 0.01, ***p < 0.001, versus the control cells; #p < 0.05, ##p < 0.01, ###p < 0.001, H₂O₂ treated cells versus the H₂O₂ and Les-236 treated cells.
33.35%, 39.44%, and 39.66%, respectively, for the BJ cell line, compared to control. In other cell lines (CACO-2, SCC-15, and SH-SY5Y), Les-236 decreased resazurin reduction at all the studied micromolar concentrations (1, 10, 50, and 100 μM) by 22.83–50.04% (Fig. 5B). After 48 h of exposure to Les-236, a decrease in resazurin reduction was observed in BJ and A549 cell lines at 10, 50, and 100 μM concentrations (by 20.01–51.36% compared to control).

Figure 4. Effect of Les-236 on the release of lactate dehydrogenase (LDH) in cultured human cell lines after (A) 3, (B) 6, and (C) 24 h of exposure. The data are presented as means ± SD of three independent experiments. Each treatment was repeated six times (n = 6), and the values were measured in triplicate.

| assay     | IC50 (μM) BJ | CACO-2 | SCC-15 | A549 | SH-SY5Y |
|-----------|--------------|--------|--------|------|---------|
| resazurine| 48.34\(^c\) (±2.07) | 12.71\(^b\) (±1.06) | 64.23\(^d\) (±5.10) | 2062.00\(^e\) (±16.02) | 0.24\(^a\) (±0.02) |
| assay     | EC50 (μM) LDH | 5.59\(^b\) (±0.04) | nd | nd | nd | 0.37\(^a\) (±0.04) |
| caspase-3 | 29.52\(^b\) (±2.14) | 10.36\(^a\) (±1.34) | nd | nd | 12.93\(^a\) (±1.82) |

Table 1. IC50 and EC50 value (in μM of Les-236) for resazurin reduction assay, caspase-3 activity assay and LDH release assay after 48 h. Different lower case letters for each assay indicate significant differences (p < 0.05). nd – not detected.
Les-236 decreases resazurin reduction in cancerous cell lines. In the SCC-15 cells, Les-236 decreased resazurin reduction at 1, 10, 50, and 100 µM concentrations by 25.06%, 39.44%, 46.02%, and 49.71% compared to control. In the CACO-2 cell line, Les-236 decreased resazurin reduction at concentrations from 100 nM to 100 µM by 13.66–66.92%, compared to control. The strongest decrease in resazurin reduction was observed in the SH-SY5Y cell line. Les-236 decreased the reduction of resazurin by 37.80–91.32% at concentrations from 50 nM to 100 µM compared to control (Fig. 5C). The strongest potential of Les-236 to inhibit cell metabolism/proliferation measured by resazurine reduction was noted in the SH-SY5Y cell line at 0.24 µM and the weakest in the A549 cell line at 2062.00 µM (Table 1).

Les-236 increases caspase-3 activity in cancerous cell lines. After 6 h of exposure of CACO-2 and SH-SY5Y cell lines to Les-236, we observed an increase in caspase-3 activity by 182.20–212.10% compared to control at concentrations of 50 and 100 µM. Interestingly, in the A549 cell line, an increase in caspase-3 activity was observed at concentrations of 10 and 50 µM (by 104.90% and 76.54%, respectively, compared to control). In the SCC-15 cell line, Les-236 increased caspase-3 activity at 10, 50, and 100 µM concentrations (by 128.05%, 1108.15%, and 1308.54%, respectively, compared to control). The strongest increase in caspase-3 activity by Les-236 was observed in the BJ cell line where Les-236 increased caspase-3 activity at all studied concentrations (1 nM to 100 µM) by 111.42–495.56% compared to control (Fig. 6A). After 24 h of exposure of the SH-SY5Y cell line to Les-236, an increase in caspase-3 activity was observed at concentrations of 50 and 100 µM (by 278.22% and 295.34%, respectively, compared to control). In the CACO-2 cell line, Les-236 increased caspase-3 activity at 10, 50, and 100 µM concentrations by 60.00%, 578.34%, and 261.74%, respectively, compared to control. In BJ and SCC-15 cell lines, Les-236 increased the caspase-3 activity at all the studied micromolar concentrations (1, 10,
50, and 100 µM) by 42.42–1324.24%, compared to control. Interestingly, Les-236 increased caspase-3 activity in the A549 cell line at all the studied concentrations by 40.00–220.00% compared to control (Fig. 6B). After 48 h of exposure of the BJ cell line, Les-236 increased the activity of caspase-3 (by 255.11% and 304.04%, respectively, compared to control) only at the highest micromolar concentrations of 50 and 100 µM. In the SH-SY5Y cell line, Les-236 increased caspase-3 activity at concentrations of 10, 50, and 100 µM (31.76%, 358.82%, and 351.05%, respectively, compared to control). In A549 cell line, Les-236 increased caspase-3 activity at concentrations from 1 nM to 50 µM (by 39.26–248.15%, compared to control). In CACO-2 and SCC-15 cell lines, Les-236 increased caspase-3 activity at all studied concentrations (1 nM to 100 µM) by 39.13–711.64%, compared to control (Fig. 6C). EC_{50} was calculated for caspase-3 activity to determine the dose-dependent effect on cell lethality (Table 1).

Les-236 affects mRNA expression of PPARγ in cancerous cell lines. After 6 h of exposure of the BJ cell line to 1 and 10 µM concentrations of Les-236, there was an increase in the expression of PPARγ by 25.76% and 17.31%, respectively. In the A549 cell line, 1 and 10 µM concentrations of Les-236 similarly increased expression of PPARγ by 36.03% and 23.33%, respectively. In the SH-SY5Y cell line, an increase in PPARγ expression was observed after treatment with 1 µM Les-236 (increased by 25.03% compared to control). In the SCC-15 cell line, a decrease in PPARγ expression was observed after treatment with 1 µM Les-236 (decreased by 12.26% compared to control). In the CACO-2 cell line, 1 and 10 µM concentrations of Les-236 decreased the expression of PPARγ by 21.67% and 36.25%, respectively (Fig. 7).

Figure 6. Effect of Les-236 on caspase-3 activity in cultured human cell lines after (A) 3, (B) 6, and (C) 24 h of exposure. The data are presented as means ± SD of three independent experiments. Each treatment was repeated six times (n = 6), and the values were measured in triplicate.
Les-236 affects protein expression of PPARγ and KI67 in cancerous cell lines. After 48 h exposure of the BJ cell line to 1 μM Les-236, no changes in the PPARγ protein expression were observed. Both the agonist (rosiglitazone) and the antagonist (GW9662) of PPARγ decreased protein expression of PPARγ (1.15 and 1.16 ng/mL, respectively, compared to control). Cell co-treatment with Les-236 and rosiglitazone or Les-236 and GW9662 did not affect expression of PPARγ compared to rosiglitazone alone or GW9662 alone, respectively. Similarly, in CACO-2 cells, 1 μM Les-236 did not affect expression of PPARγ. Rosiglitazone increased PPARγ protein expression by 5.83 ng/mL. GW9662 decreased PPARγ protein expression in CACO-2 cells by 2.03 ng/mL. Les-236 prevented decrease in PPARγ protein expression caused by GW9662. In SCC-15 cells, 1 μM Les-236 decreased in PPARγ expression by 4.47 ng/mL. Interestingly, GW9662 increased PPARγ expression by 6.96 ng/mL. Les-236

Figure 7. Effect of 1 and 10 μM Les-236 on mRNA expression of PPARγ after 6 h of exposure in cultured human cell lines after mRNA expression was normalized to β-actin. The data are expressed as means ± SD of three independent experiments, each of which consisted of six replicates per treatment group. *p < 0.05; **p < 0.01; ***p < 0.001 vs. the vehicle control.
decreased expression of PPARγ stimulated by GW9662 (decreased by 12.42 ng/mL compared to GW9662 stimulated cells). After the exposure of A549 cells to 1 µM Les-236, no changes in the PPARγ protein expression were observed. Cell co-treatment with Les-236 and rosiglitazone increased PPARγ protein expression compared to the rosiglitazone treated group (increased by 1.04 ng/mL). After 48 h of exposure of the SH-SY5Y cell line to 1 µM Les-236, a decrease in the PPARγ protein expression was observed (decreased by 0.63 ng/mL). Cell stimulation with rosiglitazone and GW9662 decreased PPARγ expression by 0.31 and 0.70 ng/mL, respectively compared to control. Cell co-stimulation with Les-236 and rosiglitazone or Les-236 and GW9662 enhanced the effect of rosiglitazone or GW9662 alone (Fig. 8).

After 48 h exposure of the BJ cell line to 1 µM Les-236, Ki67 protein expression decreased by 0.12 ng/mL, compared to control. Rosiglitazone did not affect Ki67 protein expression. GW9662 decreased protein expression of Ki67 by 0.15 ng/mL compared to control. Cell co-treatment with Les-236 and rosiglitazone or Les-236 and GW9662 did not affect expression of Ki67 to rosiglitazone or GW9662 alone, respectively. In CACO-2 cells, 1 µM Les-236 did not affect expression of Ki67. Rosiglitazone increased PPARγ protein expression by 9.42 ng/mL. Les-236 potentiated the effect of rosiglitazone by 11.01 ng/mL compared to the rosiglitazone treated group. GW9662 decreased Ki67 protein expression in CACO-2 cells by 6.01 ng/mL. Les-236 prevented decrease in Ki67 protein expression caused by GW9662. In SCC-15 cells, Les-236, rosiglitazone or GW9662 alone did not affect Ki67 protein expression. Interestingly, SCC-15 cell co-treatment with rosiglitazone and Les-236 or GW9662 and les-236 increased in Ki67 expression by 1.02 and 0.29 ng/mL, respectively compared to control. After A549 cell line exposure to 1 µM Les-236, no changes in the Ki67 protein expression were observed. Rosiglitazone alone increased Ki67 protein expression (increased by 0.47 ng/mL compared to control); however cell co-treatment with Les-236 and rosiglitazone did not affect Ki67 expression, compared to the rosiglitazone treated group. GW9662 did not affect Ki67 protein expression of A549 cells but cell co-treatment with Les-236 and GW9662 decreased expression of Ki67 (decreased by 0.57 ng/mL, compared to GW9662 treated group). In the SH-SY5Y cell line, 1 µM Les-236 decreased Ki67 protein expression by 0.16 ng/mL, compared to control. Cell stimulation with rosiglitazone and GW9662 decreased PPARγ expression by 0.15 and 0.25 ng/mL, respectively compared to control. Cell co-stimulation with Les-236 and rosiglitazone or Les-236 and GW9662 did not affect the expression of Ki67 compared to rosiglitazone or GW9662 alone (Fig. 9).

Discussion

The International Agency for Research on Cancer estimated that there were 9.6 million cancer deaths in 2018.2 Such statistic indicates that cancer is the second most common cause of death worldwide after cardiovascular diseases. Therefore, there is an urgent need to find an effective cure for cancer. As 5-ene-2-amino(imi-no)-4-thiazolidinones showed a positive anticancer activity in a previous screening,46 we decided to study the anticancer potential of SZ-(4-fluorobenzylidene)-2-(4-hydroxyphenylamino)-thiazol-4-one (Les-236) in the following four human cancer cell lines: squamous cell carcinoma (SCC-15), lung carcinoma (A549), colon adenocarcinoma (Caco-2), and neuroblastoma (SH-SY5Y). Our experiments showed a decrease in ROS production in all the studied cancer cell lines (Scc-15, Caco-2, A549, and SH-SY5Y) and the normal skin fibroblast cell line (BJ) under the action of Les-236. The strongest decrease in ROS production in all the time intervals was observed in Caco-2 cell line, while SH-SY5Y cell lines showed the least sensitivity to Les-236. Moreover, in all studied cell lines, cell co-treatment with H2O2 and Les-236 showed that Les-236 reduced ROS production stimulated by H2O2. Currently, there is evidence that the mechanism of anticancer activity of structurally similar 4-thiazolidinones is associated with increase in the level of ROS19,37. However, our data suggest a different mechanism for the activity of Les-236. Similar results have been previously obtained by Kobylnska et al. (2016) who studied the activity of 5-hetarylidene 2-(4,5-dihydropyrazol-1-yl)-4-oxo-4,5-dihydo-1,3-thiazoles in rat glioma (C6) cell line33. The compound studied by Kobylnska et al. (2017) also decreased ROS production in human glioma (U251) cell line34. Moreover, decrease in ROS production correlated with decrease in the activity of superoxide dismutase and increase in the activity of catalase51. Due to similarities in chemical structure between the two compounds, we believed that Les-236 might act in a similar way.

Our study showed that despite decrease in production of ROS, the Les-236 compound exhibited cytotoxicity. The strongest induction of LDH release was observed in BJ, SCC-15, and SH-SY5Y cell lines. The resazurin reduction assay revealed that Les-236 decreased metabolism/proliferation in all the studied cell lines at micromolar concentrations, with the strongest reduction observed in SH-SY5Y cell line. All the tests showed that neuroblastoma was very sensitive to Les-236, as the compound caused necrosis in the SH-SY5Y cell line.

To date, it has been described that high in vitro concentrations (µM) of thiazolidinediones (TZDs), such as ciglitazone, rosiglitazone, pioglitazone, and troglitazone, lead to cell cycle arrest, apoptosis, and redifferentiation42-45, suggesting a putative link between PPARγ signaling and the antitumor activities of TZDs. The mentioned TZDs were shown to increase LDH release in mouse glioma cells (GL261), C6, human colorectal adenocarcinoma (HT29), and human colon carcinoma (COLO-205) cell lines46-50, as well as decrease cell metabolism/proliferation in human breast cancer (MCF-7), A549, and human prostate cancer (PC-3) cell lines.50,58,59 Furthermore, the in vivo anticancer efficacy of troglitazone was demonstrated in a few clinical studies that involved patients with liposarcomas or prostate cancer.45 Similar to our study, Kobylnska et al.53,54 showed that a new derivative of 4-thiazolidinone (Les-3288) decreased cell metabolism/proliferation as revealed by the MTT assay in C6 and U251 cells. Our previous studies showed that 4-thiazolidinone derivatives (Les-2194, Les-3377, Les-3640) caused LDH release and decrease of resazurin reduction in SCC-15 cell lines.57 Moreover, PPARγ silencing reduced the toxicity of related thiazolidinones (Les-2194, Les-3377, Les-3640) which confirms the crucial role of PPARγ receptors in the mechanism of action of 4-thiazolidinone derivatives50.

The most important marker of apoptosis is activation of caspase-3 which results in DNA fragmentation, degradation of the cytoskeleton and nuclear proteins, cross-linking of proteins, and finally, formation of apoptotic bodies.60 Our study showed that after 6 h of exposure to Les-236, caspase-3 activity increased in the BJ cell line.
at all studied concentrations. In cancer cell lines (SCC-15, CACO-2, A549, and SH-SY5Y), caspase-3 activity was increased only at micromolar concentrations after 6 and 24 h of exposure to Les-236. Interestingly, after 48 h of exposure, Les-236 caused caspase-3 activation at all studied concentrations in A549 (excluding 100 µM which is a highly necrotic concentration), CACO-2, and SCC-15 cell lines. The observation that Les-236 also caused caspase-3 activation in normal skin fibroblasts (BJ) is disturbing. The long duration of exposure needed

Figure 8. Effect of 1 µM Les-236 or co-treatment with 10 µM rosiglitazone or 10 µM GW9662 on protein expression of PPARγ after 24 h of exposure. Protein expression was normalized to the total protein level. Data are expressed as means ± SE of three independent experiments. *p < 0.05; **p < 0.01; ***p < 0.001 vs. vehicle control. ##p < 0.01; ###p < 0.001 rosiglitazone vs. Les236 with rosiglitazone. $$$p < 0.001 GW9662 vs. GW9662 treated cells.
for apoptosis activation in A549, CACO-2, and SCC-15 cell lines suggests the complex mechanism of action of Les-236 and its promising effect in cancer treatment. Moreover, in A549, CACO-2, and SCC-15 cell lines, apoptosis correlated with increase in expression and/or activation of PPARγ.** Our previous study showed that Les-3377 and Les-3640 increased caspase-3 activity in SCC-15 cells, and silencing of PPARγ prevented the activation of caspase-3.**
The half-maximal inhibitory concentration (IC_{50}) is the most widely used and informative measure of a drug’s efficacy. It indicates how much drug is needed to inhibit a biological process by half, thus providing a measure of the potency of an antagonist drug in pharmacological research. As measured by resazurine reduction, Les-236 has the highest potential to inhibit cell metabolism/proliferation in the SH-SY5Y cell line (0.24 μM) and the weakest in the A549 cell line (2062.00 μM) (Table 1). The half maximal effective concentration (EC_{50}) level is a well-known quantity used in pharmacology and toxicology to calculate the efficacy of a substance from a dose–response curve. It represents the dose at which 50% of the maximum efficacy is observed. EC_{50} values were calculated for LDH release and caspase-3 activity to determine the dose-dependent effect on lethality to cells. The lowest EC_{50} for LDH release was for the SH-SY5Y (0.37 μM) cell line. For caspase-3 assay, the lowest EC_{50} was for the Caco-2 cell line (10.36 μM).

In the second part of our study we showed that after cell exposure to 1 μM Les-236, KI67 protein (considered as a marker of proliferation) expression significantly decreased in BJ and SH-SY5Y cell lines which correlates with decreased resazurine reduction. In the mentioned cell lines, co-stimulation with Les-236 and rosiglitazone (PPAR_{γ} agonist) or GW9662 (PPAR_{γ} antagonist) did not affect expression of KI67 decreased by Les-236. In Caco-2, SCC-15 and A549 cell lines, 1 μM Les-236 did not affect KI67 protein expression. In the Caco-2 cell line, cell co-stimulation with Les-236 and rosiglitazone increased expression of KI67. In the A549 cell line, co-treatment with Les-236 and GW9662 decreased KI67 protein expression. Interestingly, in the SCC-15 cell line, co-stimulation with both, Les-236 and rosiglitazone and Les-236 and GW9662, increased KI67 protein expression. As mentioned above, in vitro studies, high concentrations (μM) of TZDs, led to cell cycle arrest, apoptosis, and redifferentiation. However, in some cell lines, such as SCC, A549 and Caco-2, TZDs can stimulate cells proliferation depending on the concentration. Our experiments show that after a 6 h exposure, Les-236 affects PPAR_{γ} mRNA expression in all studied cell lines. Moreover, Les-236 alone or in co-treatment with rosiglitazone or GW9662, affects expression of PPAR_{γ} protein in the studied cell lines. In Caco-2, A549, and SH-SY5Y cell lines, Les-236 acts similar to GW9662. In the SCC-15 cell line, Les-236 acts similar to rosiglitazone. Unfortunately, in the BJ cell line, results are not conclusive and we cannot clearly determine whether Les-236 works similar to an agonist or an antagonist of PPAR_{γ}. We suggest that in the A549, Caco-2, and SCC-15 cell lines, PPAR_{γ}-dependent pathways could be involved in cell death caused by Les-236; however, more studies are needed to confirm this hypothesis.

In conclusion, our results showed the anticancer potential of 5′-(4-fluorobenzylidene)-2′-(4-hydroxyphenylamino)-thiazol-4-one (Les-236) toward the human cancer cell lines. The studied compound decreased ROS production in BJ, SCC-15, Caco-2, A549, and SH-SY5Y cell lines at micromolar concentrations. However, the compound increased LDH release and decreased cell metabolism/proliferation at micromolar concentrations in BJ, SCC-15, Caco-2, A549, and SH-SY5Y cell lines. Les-236 was able to increase the activity of caspase-3 in BJ (after 6 h of exposure), A549, Caco-2, and SCC-15 (after 48 h of exposure) cell lines over a wide range of concentrations (1 nM to 100 μM), which could be due to the activation of PPAR_{γ}-dependent pathways. However, the safety of this compound and its metabolites should be examined in other normal human cells. Therefore, further studies on the mechanism underlying the effects of Les-236 in vitro and in vivo are needed.

Materials and Methods
Reagents.
Trypsin, penicillin, streptomycin, phosphate-buffered saline without Ca^{2+} and Mg^{2+}, hydrocortisone, sodium pyruvate, sodium bicarbonate, dimethyl sulfoxide (DMSO), caspase-3 substrate (235400), 2′,7′-dichlorodihydrofluorescein diacetate (H₂DCFDA) (D6883), GW9662, rosiglitazone, hydrogen peroxide (H₂O₂) and resazurin (R7017) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Black 96-well culture plates (655090) were purchased from Greiner Bio-One (Frickenhausen, Germany). Charcoal/dextran-treated fetal ovine serum (FBS), heat-inactivated FBS, RNA isolation kit (E0039), and fast probe real-time PCR master mix (RoX) (E0423) were purchased from ROCHE Applied Science (Mannheim, Germany). The High Capacity cDNA Reverse Transcription Kit and the TaqMan® probes corresponding to specific genes encoding β-Actin (Hs01060665_g1) and PPAR_{γ} (Hs00234592_m1) were purchased from Life Technologies (Forest City, CA, USA). PPAR_{γ} (H1361) and KI67P (H5432) ELISA assays were obtained from Elabscience Biotechnology (Wuhan, China).

The synthesis and physicochemical properties of the tested compound 5′-(4-fluorobenzylidene)-2′-(4-hydroxyphenylamino)-thiazol-4-one (Les-236) were described previously (Fig. 1). This compound was selected based on the results of a previous screening.

Cell culture.
Human squamous cell carcinoma (SCC-15), lung carcinoma (A549), colon adenocarcinoma (Caco-2), neuroblastoma (SH-SY5Y), and skin fibroblast (BJ) cell lines were obtained from the American Type Culture Collection (ATCC, distributor: IGC Standards, Lomianki, Poland). The A549 cell line was maintained in the F12K medium, SCC-15 and SH-SY5Y cell lines were maintained in the DMEM/F12 medium and BJ and Caco-2 cell lines were maintained in the MEM medium. The media used in the experiments were phenol red-free and contained 2.5 mM L-glutamine. Moreover, the media were supplemented with 10% FBS (or heat-inactivated FBS for SH-SY5Y cells) and 400 ng/mL hydrocortisone (only for SCC-15 cells). The cells were maintained in an incubator at 37°C in a humidified atmosphere with 5% CO₂. For ROS measurements, lactate dehydrogenase (LDH) release, resazurine reduction and caspase-3 activity assays, the cells were seeded in 96-well culture plates at a density of 6 x 10⁴ (for 6 and 24 h treatments) and 5 x 10⁵ (for 48 h treatment) per well and initially cultured before the experiment for 24 h. For the real-time PCR assay, different cell lines were seeded onto 12-well plates and initially cultured for 24 h. For the protein measurement, different cell lines were seeded onto 6-well plates and initially cultured for 24 h. Subsequently, the medium was replaced with a fresh one by raising the concentrations (1, 10, 50, and 100 nM and 1, 10, 50, and 100 μM) of the studied compound Les-236.
Estimation of ROS production. To determine the ability of Les-236 to induce ROS production in the cells, 5 µM H2DCFDA was applied. The cells were incubated with H2DCFDA in serum-free and phenol red-free medium for 45 min before treatment with increasing (1, 10, 50, and 100 nM and 1, 10, 50, and 100 µM) concentrations of the studied compound according to a previously described method. After incubating the cells for 3, 6, and 24 h with increasing concentrations of the compound (and 5% CO2 at 37 °C), the culture medium was replaced with a fresh one to remove extracellular residual dichlorodihydrofluorescein (DCF). Cells treated with 100 µM hydrogen peroxide (H2O2) were used as a positive control (results not shown). DCF fluorescence was measured using a microplate reader (FilterMax F5) at the maximum excitation and emission spectra of 485 and 535 nm, respectively.

LDH cytotoxicity assay. The cytotoxicity detection kit is used for colorimetric assay to quantify the cell death: necrosis and secondary necrosis (after the disintegration of the apoptotic bodies in the cell culture environment). The assay was based on cell lysis and the release of LDH from the cytosol of the damaged cells into the surrounding medium. After 6, 24, and 48 h of treatment of the cells with increasing concentrations of the studied compound, 100 µL of the culture supernatants was collected and incubated in the reaction mixture from the kit according to the manufacturer’s protocol. After 30 min, the reaction was stopped by adding 1 N HCl and the absorbance was measured at a wavelength of 490 nm using the FilterMax F5 Multi-Mode microplate reader (Molecular Devices, Corp., Sunnyvale, CA, USA).

Resazurin reduction cell viability and metabolism assay. A working solution of 60 µM resazurin was prepared in a medium containing 1% FBS on the day of analysis according to a previously described method. After 6, 24, and 48 h of treatment of cells with increasing concentrations of the Les-236 compound in 96-well culture plates, the cells in the wells were replaced by a working solution of resazurin (100 µL) and the plates were incubated at 37 °C. Fluorescence was measured at an excitation wavelength of 530 nm and an emission wavelength of 590 nm on the FilterMax F5 Multi-Mode microplate reader (Molecular Devices, Corp., Sunnyvale, CA, USA) after 30 and 60 min of dye addition.

Caspase-3 activity. Caspase-3 activity was used as a marker of cell apoptosis. After 6, 24, and 48 h of treatment of cells with increasing concentrations of Les-236, the culture plates were frozen at −80 °C and left until assay. The frozen cells were lysed with lysis buffer (50 mM HEPES (pH 7.4), 100 mM NaCl, 0.1% CHAPS, 1 mM EDTA, 10% glycerol, and 10 mM DTT) at 10 °C for 10 min according to a previously described protocol. The lysates were incubated with caspase-3 substrate Ac-DEVD-pNA at 37 °C. Cells treated with 1 µM staurosporine were used as a positive control (results not shown). After 30 min, the absorbance of the lysates at 405 nm was measured using the FilterMax F5 Multi-Mode microplate reader. The amount of colorimetric product produced was continuously monitored for 120 min. The data were analyzed using Multi-Mode Analysis software (Molecular Devices, Corp., Sunnyvale, CA, USA) and were normalized to absorbance of the vehicle-treated cells.

Real-time PCR analysis of mRNAs specific to genes encoding PPARγ. The experiment was conducted as per a previously described procedure. After a 6 h exposure to 1 or 10 µM Les236, the samples were collected and total RNA was extracted from the cells using an RNA isolation kit according to the manufacturer’s instructions. The quantity and quality of the RNA were determined spectrophotometrically at 260 and 280 nm, respectively (NanoDrop ND/1000 UV/Vis, Thermo Fisher, USA). Two-step real-time reverse transcription (RT) PCR was conducted, with both the RT reaction and the quantitative PCR (qPCR) run using the CFX Real Time System (BioRad, USA). The RT reaction was carried out at a final volume of 20 µL with 250 ng RNA (as a cDNA template) using the cDNA reverse transcription kit in accordance with the manufacturer’s instructions. Products from the RT reaction were amplified using the fast probe qPCR master mix (RoX) kit with TaqMan probes as primers for specific genes encoding ACTB and PPARγ. Amplification was carried out in a total volume of 25 µL containing 1 × fast probe qPCR master mix (RoX) and 1.0 µL of the RT product which was used as the PCR template. Standard qPCR procedures were carried out as follows: 2 min at 50 °C and 10 min at 95 °C, followed by 45 cycles of 15 s at 95 °C and 1 min at 60 °C. The threshold value (Ct) for each sample was set during the exponential phase, and the ΔΔCt method was used for data analysis. ACTB was used as the reference gene.

ELISA for PPARγ and Ki67. The levels of PPARγ and Ki67 proteins were determined through ELISA after a 48 h treatment with 1 µM Les236 or co-treatment with Les-236 and 10 µM rosiglitazone or Les-236 and GW9662. These proteins were specifically detected with ELISA and subsequently subjected to quantitative sandwich enzyme immunoassay, which was conducted according to the manufacturer’s instructions (Elabscience Biotechnology, Wuhan, China). Briefly, a 96-well plate was pre-coated with monoclonal antibodies specific to PPARγ and Ki67. Standards and the collected cell extracts were added to the wells and incubated for 90 min at 37 °C. Next, the liquid was removed, and biotinylated detection antibodies (100 µL) were added to the cultures for 60 min. We washed the cells three times to remove any unbound substances, and then added horseradish peroxidase-conjugated avidin. The cells were washed again, and 90 µL of substrate solution was added to the wells for 15 min. Then, 50 µL stop solution was added to terminate the reaction and the absorbance was measured at 450 nm; the value obtained was proportional to the amount of PPARγ and Ki67, respectively. The total protein concentration was determined in triplicate in each sample by using a Thermo Fisher NanoDrop device.

Statistical analysis. The data are presented as means ± SD of three independent experiments. Each treatment was repeated six times (n = 6), and the values were measured in triplicate. The average of the triplicate samples was used for the statistical analyses. Considering the difference in data obtained from the measurement
of fluorescence and absorbance, the results were presented as a percentage of the controls. The data were analyzed using one-way analysis of variance followed by Tukey’s multiple comparison procedure; *p < 0.05, **p < 0.01, and ***p < 0.001 vs. control cells were considered significant. Statistical significance is marked on the figures (Figs 3, 7, 8, 9) or in the supplementary data (Figs 2, 4, 5, 6).

Highlights.

- Les-236 decreased the production of reactive oxygen species in BJ, SCC-15, CACO-2, A549, and SH-SY5Y cell lines.
- At high micromolar concentrations, Les-236 increased the release of lactate dehydrogenase in all the studied cell lines.
- Les-236 activated caspase-3 in A549, CACO-2, and SCC-15 cell lines at all the studied concentrations.
- PPARγ is involved in Les-236 mechanism of action.

References

1. Kaminskyy, D., Kryshchyshyn, A. & Lesyk, R. 5-Ene-4-thiazolidinones – An efficient tool in medicinal chemistry. *Eur J Med Chem* **140**, 542–594 (2017).
2. Tripathi, A. C. *et al.* 4-Thiazolidinones: The advances continue…. *Eur J Med Chem* **72**, 52–77 (2014).
3. Asati, V., Mahapatra, D. K. & Bharti, S. K. Thiazolidine-2,4-diones as multi-targeted scaffold in medicinal chemistry: Potential anticancer agents. *Eur J Med Chem* **87**, 814–833 (2014).
4. Kaminskyy, D., Zimenkovsky, B. & Lesyk, R. Synthesis and in vitro anticancer activity of 2,4-azolidinedione-acetic acids derivatives. *Eur J Med Chem* **44**, 3627–3636 (2009).
5. Kaminskyy, D., Khylik, D., Vasylenko, O., Zaprutko, L. & Lesyk, R. A facile synthesis and anticancer activity evaluation of spiro[Thiazolidinone-isatin] conjugates. *Sci Pharm*. **79**, 763–777 (2011).
6. Kaminskyy, D. *et al.* Synthesis and evaluation of anticancer activity of 5-yldiene-4-aminothiazol-2(5H)–one derivatives. *Med Chem (Los. Angeles)*. **11**, 517–530 (2015).
7. Kaminskyy, D., Kryshchyshyn, A. & Lesyk, R. Recent developments with rhodanine as a scaffold for drug discovery. *Expert Opin Drug Discov* **12**, 1233–1252 (2017).
8. Baell, J. B. & Holloway, G. A. New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays. *J Med Chem* **53**, 2719–2740 (2010).
9. Mendgen, T., Steuer, C. & Klein, C. D. Privileged Scaffolds or Promiscuous Binders: A Comparative Study on Rhodanines and Related Heterocycles in Medicinal Chemistry. *J Med Chem* **55**, 743–753 (2012).
10. Baell, J. B. & Nissink, J. W. M. Seven Year Itch: Pan-Assay Interference Compounds (PAINS) in 2017 - Utility and Limitations. *ACS Chem Biol* **13**, 36–44 (2018).
11. Forman, H. J., Davies, K. J. & Ursini, F. How do nutritional antioxidants really work? Nucleophilic tone and para-hormesis versus free radical scavenging in vivo. *Free Radiic Biol Med*. **66**, 24–35 (2014).
12. Dinkova-Kostova, A. T., Massiah, M. A., Bozak, R. E., Hicks, R. J. & Talalay, P. Potency of Michael reaction acceptors as inducers of enzymes that protect against carcinogenesis depends on their reactivity with sulfhydryl groups. *Proc Natl Acad Sci* **98**, 3404–3409 (2001).
13. Jackson, P. A., Widen, J. C., Hanki, D. A. & Brummond, K. M. Covalent Modifiers: A Chemical Perspective on the Reactivity of α,β-Unsaturated Carbonyls with Thiols via Hetero-Michael Addition Reactions. *J Med Chem* **60**, 839–885 (2017).
14. Parvez, S., Long, M. J. C., Poganik, J. R. & Aye, Y. Redox Signaling by Reactive Electrophiles and Oxidants. *Chem Rev* **118**, 8798–8888 (2018).
15. Harvyylyuk, D. *et al.* Synthesis and anticancer activity evaluation of 4-thiazolidinones containing benzothiazole moiety. *Eur J Med Chem* **45**, 5012–5021 (2010).
16. SubtelNa, I. *et al.* Synthesis of 5-arylidene-2-amino-4-azolones and evaluation of their anticancer activity. *Bioorganic Med Chem* **18**, 5090–5102 (2010).
17. Ottanà, R. *et al.* In vitro antiproliferative activity against human colon cancer cell lines of representative 4-thiazolidinones. *Part I: Bioorganic Med Chem Lett.* **15**, 3930–3933 (2005).
18. Zhou, H. *et al.* Design, Synthesis, Cytoselective Toxicity, Structure–Activity Relationships, and Pharmacophore of Thiazolidinone Derivatives Targeting Drug-Resistant Lung Cancer Cells. *J Med Chem* **51**, 1242–1251 (2008).
19. Senkiv, J. *et al.* 5–Ene–4-thiazolidinones induce apoptosis in mammalian leukemia cells. *Eur J Med Chem* **117**, 33–46 (2016).
20. Szychowski, K. A. *et al.* Anticancer properties of 4-thiazolidinone derivatives depend on peroxisome proliferator-activated receptor gamma (PPARγ). *Eur J Med Chem* **141**, 162–168 (2017).
21. Fang, B., Wu, S. & Teraishi, F. Thiazolone compounds for treatment of cancer (2005).
22. Dayan, R. *et al.* Discovery of Small Molecule Integrin αvβ3 Antagonists as Novel Anticancer Agents. *J Med Chem* **49**, 4526–4534 (2006).
23. Chen, S. *et al.* Synthesis and activity of quinolinyl-methylene-thiazolineones as potent and selective cyclin-dependent kinase 1 inhibitors. *Bioorg Med Chem Lett* **17**, 2134–8 (2007).
24. Jorda, R. *et al.* Flow Selective Are Pharmacological Inhibitors of Cell-Cycle-Regulating Cyclin-Dependent Kinases? *J Med Chem* **61**, 9105–9120 (2018).
25. Lu, W. *et al.* HiL005 - A new selective PPARγ antagonist specifically inhibits the proliferation of MCF-7. *J Steroid Biochem Mol Biol* **124**, 112–120 (2011).
26. Chisamore, M. J., Wilkinson, H. A., Flores, O. & Chen, J. D. Estrogen-related receptor-antagonist inhibits both estrogen receptor-positive and estrogen receptor-negative breast tumor growth in mouse xenografts. *Mol Cancer Ther* **8**, 672–681 (2009).
27. Geronikaki, A. *et al.* 2-Thiazolylmimino/Heteroarylimino-5-arylidene-4-thiazolidinones as New Agents with SHP-2 Inhibitory Action. *J Med Chem* **51**, 5221–5228 (2008).
28. Meng, G. *et al.* Design and synthesis of new potent PTPIB inhibitors with the skeleton of 2-substituted imino-3-substituted 5-heteroarylidine-1,3-thiazol-4-one: Part 1. *Eur J Med Chem* **122**, 756–769 (2016).
29. War, J. A., Srivastava, S. K. & Srivastava, S. D. Synthesis and DNA-binding study of imidazole linked thiazolidine derivatives. *Luminescence* **32**, 104–113 (2017).
30. Jain, V. S., Vora, D. K. & Ramaa, C. S. Thiazolidine-2,4-diones: Progress towards multifarious applications. *Bioorg Med Chem* **21**, 1599–1620 (2013).
31. Teraishi, F. *et al.* P-Glycoprotein-Independent Apoptosis Induction by a Novel Synthetic Compound, MMPT [5-[[4-Methylphenyl]methylene]-2’-(phenylamino)-4(5H)-thiazolone]. *Pharmacology* **314**, 355–362 (2005).
32. Revelant, G. et al. Synthesis and biological evaluation of novel 2-heteroaryl-5-hydroxy-1,3-thiazol-4-ones as potential anti-tumor agents. J. Med. Chem. 94, 102–112 (2015).
33. Panchuk, R. R. et al. Study of molecular mechanisms of proapoptotic action of novel heterocyclic 4-thiazolidone derivatives. Biopolym. Cell 28, 121–128 (2012).
34. Teng, X. et al. Structure–activity relationship study of novel necroptosis inhibitors. Bioorg. Med. Chem. Lett. 15, 5039–5044 (2005).
35. Zheng, W., Degerete, A., Hsu, L., Yuan, J. & Yuan, C. Structure–activity relationship study of a novel necroptosis inhibitor, necrostatin-7. Bioorg. Med. Chem. Lett. 18, 4932–4935 (2008).
36. Geronikaki, A. A., Pitta, E. P. & Liaras, K. S. Thiazoles and thiazolindiones as antioxidants. Curr. Med. Chem. 20, 4460–80 (2013).
37. Szychowski, K. A. et al. Study of novel anticancer 4-thiazolidone derivatives. Chem. Biol. Interact. 262, 46–56 (2017).
38. Campbell, M. J., Carlberg, C. & Koeffler, H. P. A Role for the PPARgamma in Cancer Therapy. PPAR Res. 2008, 314974 (2008).
39. Celman, L., Frucht, J. C. & Auwers, J. An update on the mechanisms of action of the peroxisome proliferator-activated receptors (PPARs) and their roles in inflammation and cancer. Cell. Mol. Life Sci. 55, 93–143 (1999).
40. Elrod, H. A. & Sun, S.-Y. PPARgamma and Apoptosis in Cancer. PPAR Res. 2008, 704165 (2008).
41. Belfiore, A., Genua, M. & Malaguarnera, R. PPARγ agonists and their effects on IGF-I receptor signaling: Implications for cancer. PPAR Res. 2009, 830501 (2009).
42. Grommes, C., Landreth, G. E. & Heneka, M. T. Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. Lancet Oncol. 5, 419–29 (2004).
43. Koeffler, H. P. Peroxisome proliferator-activated receptor gamma and cancers. Clin. Cancer Res. 9, 1–9 (2003).
44. Wang, J.-R., Chen, C.-Y., Pinzone, J. J., Ringel, M. D. & Chen, C.-S. Beyond peroxisome proliferator-activated receptor gamma signaling: the multi-facets of the anti-tumor effect of thiazolidinediones. Endocr. Relat. Cancer 13, 401–413 (2006).
45. Demetri, G. D. et al. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc. Natl. Acad. Sci. USA 96, 3951–6 (1999).
46. Wei, S., Yang, J.-I., Lee, S.-L., Kulp, S. K. & Chen, C.-S. PPARgamma-independent antitumor effects of thiazolidinediones. Cancer Lett. 276, 119–24 (2009).
47. Terasi, F. et al. [NК]1-dependent antimitotic activity of thiazolidine compounds in human non-small-cell lung and colon cancer cells. Cell. Mol. Life Sci. 62, 2382–2389 (2005).
48. Omar, Y. M., Abu-Allah, H. H. M. & Abdel-Moty, S. G. Synthesis, biological evaluation and docking study of 1,3,4-thiadiazole-thiazolidine hybrids as anti-inflammatory agents with dual inhibition of COX-2 and 15-LOX. Bioorg. Chem. 80, 461–471 (2018).
49. Bhat, M. et al. Synthesis and evaluation of thiazolidine–pyrazole conjugates as anticancer and antimicrobial agents. Future Med. Chem. 10, 1017–1036 (2018).
50. Kryshchyshyn, A., Kaminsky, D., Grellier, P. & Lesyk, R. Trends in research of antitrypanosomal agents among synthetic heterocycles. Eur. J. Med. Chem. 85, 51–64 (2014).
51. Avdieiev, S. et al. Bradycinin antagonists and thiazolidine derivatives as new potential anti-cancer compounds. Bioorganic Med. Chem. 22, 3815–3823 (2014).
52. International Agency for Research on Cancer. Latest global cancer data: Cancer burden rises to 18.1 million new cases and 9.6 million cancer deaths in 2018. (2018).
53. Kohlynska, L. et al. Potent anticancer potential of novel 4-thiazolidinedione derivatives: cytotoxicity toward rat C6 glioma in vitro and correlation of general toxicity with the balance of free radical oxidation in rats. Croat. Med. J. 57, 151–163 (2016).
54. Kohlynska, L. I. et al. Differential pro-apoptotic effects of synthetic 4-thiazolidine derivative Les-3288, doxorubicin and temozolomide in human glioma U251 cells. Croat. Med. J. 58, 150–159 (2017).
55. Kopelowich, L., Fay, J. R., Glazer, R. I. & Crowell, J. A. Peroxisome proliferator-activated receptor modulators as potential chemopreventive agents. Mol. Cancer Ther. 1, 357–63 (2002).
56. Spagnolo, A., Grant, E. N., Glick, R., Lichtor, T. & Feinstein, D. L. Differential effects of PPARγ agonists on the metabolic properties of gliomas and astrocytes. Neurosci. Lett. 417, 72–77 (2007).
57. Yaacob, N. S., Darius, H. M. & Norazmi, M. N. Modulation of cell growth and PPARγ expression in human colorectal cancer cell lines by ciglitazone. Exp. Toxicol. Pathol. 60, 505–512 (2008).
58. Abdellatif, K. R. A., Abdelall, E. K. A., Abdelgawad, M. A., Abdelhakeem, M. M. & Omar, H. A. Design and synthesis of certain novel arylidene thiazolidine derivatives as anticancer agents. Der Pharma Chem. 7, 149–161 (2015).
59. Cilda, P. et al. Synthesis, cytotoxicity, and pro-apoptosis activity of etodolac hydrazide derivatives as anticancer agents. Arch. Pharm. (Weinheim). 346, 367–379 (2013).
60. Elmore, S. Apoptosis: a review of programmed cell death. Toxicol. Pathol. 35, 495–516 (2007).
61. Yang, J. PPARγ silencing inhibits the apoptosis of A549 cells by upregulating Bcl-2. Zhongguo Fei Ai Za Zhi 16, 125–130 (2013).
62. Schwab, M. et al. PPARgamma is a key target of butyrate-induced caspase-3 activation in the colorectal cancer cell line Caco-2. Apoptosis 11, 1801–11 (2006).
63. Chen, F. & Harrison, L. E. Cigarette smoke induces cellular proliferation and NF-κB transcriptional activity in colon cancer cells through p53 phosphorylation. Int. J. Biochem. Cell Biol. 37, 645–654 (2005).
64. Keshamouni, V. G. et al. Peroxisome proliferator-activated receptor γ activation inhibits tumor progression in non-small-cell lung cancer. Oncogene 23, 100–108 (2004).
65. Szychowski, K. A., Rybczynska-Tkaczynk, K., Leja, M. L., Wotowicz, A. K. & Gmiznski, J. Tetrabromobiphenol A (TBBPA)-stimulated reactive oxygen species (ROS) production in cell-free model using the 2,7′-dichlorodihydrofluorescein diacetate (H2DCFDA) assay—limitations of method. Environ. Sci. Pollut. Res. 23, 12246–12252 (2016).
66. Choo, D. W., Koh, J. Y. & Peters, S. Pharmacology of glutamate neurotoxicity in cortical cell culture: attenuation by NMDA antagonists. J. Neurosci. 8, 85–96 (1988).

Acknowledgements
We would like to thank Translmed Publishing Group (Cedar Hill, TX, USA), a proofreading and copyediting company, for improving the language in the manuscript. This work was supported by statutory funds of the University of Information Technology and Management in Rzeszów, Poland (DS 503–07–02–21). All authors declare they have no conflict of interest.

Author Contributions
K.A.S. designed the research. D.V.K., A.P.K. and R.B.L., synthesized the compound used in the experiments. K.A.S., M.L.L., J.T., M.W. and J.G. performed the cell culture research. K.A.S. and D.V.K. analyzed the data and wrote the manuscript. T.P. and J.G. obtained financial support for the project. All authors read and approved the manuscript.

Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-47177-6.
Competing Interests: The authors declare no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.